This page shows the latest relebactam news and features for those working in and with pharma, biotech and healthcare.
Earlier this year, the European Commission approved Recarbrio (imipenem/cilastatin/relebactam) for the treatment of infections caused by aerobic Gram-negative organisms in adults with limited treatment options. ... The regimen combines MSD’s
The regimen combines Merck’s imipenem/cilastatin duo – sold as Primaxin as a broad-spectrum antibiotic – with a new beta lactamase inhibitor called relebactam that is designed to restore the susceptibility
The regimen combines Merck’s own Primaxin with new beta lactamase inhibitor relebactam. ... Merck is also carrying out a phase III trial comparing the relebactam regimen with piperacillin/tazobactam, another widely-used antibiotic for hospital-acquired
Meanwhile, Merck &Co is also working on a beta lactamase inhibitor called relebactam, and recently started a phase III programme looking at the drug in combination with imipenem.
Continues testing after positive phase II results for relebactam addition . After positive phase II results, Merck &Co has decided to take a novel antibiotic into phase III testing. ... The first is comparing treatment with relebactam/imipenem to
tazobactam). Merck also has relebactam (MK-7655) in mid-stage trials as an intravenous treatment for acute bacterial infections.
More from news
Approximately 2 fully matching, plus 5 partially matching documents found.
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 950 experts delivering world-class...